ReviewKorean journal of neurotrauma2026
Blood-Based Biomarkers and Cognitive-Behavioral Assessment in Mild Traumatic Brain Injury: Current Evidence and Clinical Perspectives.
Review in Korean journal of neurotrauma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild traumatic brain injury (mTBI) comprises the majority of all traumatic brain injuries, but clinical evaluation remains challenging because conventional neuroimaging cannot adequately detect subtle structural abnormalities or explain functional disturbances. Blood-based biomarkers have been studied as indicators of tissue injury. They may help reduce unnecessary computed tomography scans and predict unfavorable outcomes. However, biomarkers still have limitations in accurately assessing cognitive and behavioral abnormalities. Cognitive and behavioral evaluation helps characterize the functional consequences of mTBI, including impairments in attention, memory, executive function, and emotional symptoms. Although a range of cognitive and behavioral assessment tools is available, their interpretation is also influenced by factors such as timing, comorbidities, and patient effort. Taken together, blood-based biomarkers and cognitive and behavioral assessment should be interpreted in combination to allow a more comprehensive evaluation of the patients with mTBI. In this review, we summarize blood-based biomarkers and cognitive and behavioral assessment tools in mTBI, discuss their limitations, and propose an integrated approach to support more precise and individualized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.